XASX
NXS
Market cap29mUSD
Dec 31, Last price
0.15AUD
Name
Next Science Ltd
Chart & Performance
P/E
—
P/S
1.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.95%
Rev. gr., 5y
31.32%
Revenues
23m
+2.87%
Net income
-11m
L-56.81%
CFO
-8m
L-47.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Next Science Limited operates as a medical technology firm, dedicated to the research, development, and commercialization of innovative solutions aimed at mitigating the detrimental effects of biofilms on human health. The company serves markets in both the United States and Australia, building its product portfolio on its proprietary Xbio Technology platform. Among its key offerings are: SURGX: An antimicrobial gel employed for managing surgical infections. BACTISURE: A specialized wound lavage designed to eliminate biofilm. BlastX: An antimicrobial wound gel that not only eradicates bacteria within the gel but also wards off recolonization, all while maintaining an optimal moist healing environment. XPERIENCE: A no-rinse antimicrobial solution developed specifically to deter surgical site infections. Established in 2012, Next Science Limited maintains its primary operational base in Chatswood, Australia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||